<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03657355</url>
  </required_header>
  <id_info>
    <org_study_id>ID-078-107</org_study_id>
    <nct_id>NCT03657355</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Abuse Potential of ACT-541468 in Healthy Recreational Drug Users</brief_title>
  <official_title>Randomized, Double-blind, Double-dummy, Placebo- and Active-controlled, 6-way Cross-over Study to Evaluate the Abuse Potential of Single, Oral Doses of ACT-541468 in Healthy Recreational Drug Users</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Idorsia Pharmaceuticals Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Idorsia Pharmaceuticals Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This placebo- and active controlled study will investigate the abuse potential of ACT-541468
      in healthy recreational drug users
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 7, 2018</start_date>
  <completion_date type="Actual">August 8, 2019</completion_date>
  <primary_completion_date type="Actual">August 8, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Single-center, randomized, double-blind, double-dummy, placebo- and active-controlled, 6-way cross-over study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>For blinding purposes, suvorexant and zolpidem will be over-encapsulated, whereas a matching-placebo will be used for ACT-541468.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum effect (Emax) of the Drug Liking VAS ('at this moment') over 24 h post-dose during each treatment period</measure>
    <time_frame>Duration: for up to 24 hours post-dose</time_frame>
    <description>VAS = visual analogue scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drug Liking VAS (bipolar)</measure>
    <time_frame>Duration: for up to 24 hours post-dose</time_frame>
    <description>VAS = visual analogue scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Drug Liking VAS (bipolar)</measure>
    <time_frame>Duration: for up to 12 hours post-dose</time_frame>
    <description>VAS = visual analogue scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Take Drug Again VAS (bipolar)</measure>
    <time_frame>Duration: for up to 12 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Good Effects VAS (unipolar)</measure>
    <time_frame>Duration: for up to 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug Similarity VAS</measure>
    <time_frame>Duration: for up to 1 hour post-dose</time_frame>
    <description>VAS = visual analogue scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bad Effects VAS (unipolar)</measure>
    <time_frame>Duration: for up to 24 hours post-dose</time_frame>
    <description>VAS = visual analogue scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alertness/Drowsiness VAS (bipolar)</measure>
    <time_frame>Duration: for up to 24 hours post-dose</time_frame>
    <description>VAS = visual analogue scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any Effects VAS (unipolar)</measure>
    <time_frame>Duration: for up to 24 hours post-dose</time_frame>
    <description>VAS = visual analogue scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feeling High VAS (unipolar)</measure>
    <time_frame>Duration: for up to 24 hours post-dose</time_frame>
    <description>VAS = visual analogue scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bowdle VAS Internal and External Perceptions</measure>
    <time_frame>Duration: for up to 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observer's Assessment of Alertness/Sedation composite and sum scores</measure>
    <time_frame>Duration: for up to 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reaction time task score</measure>
    <time_frame>Duration: for up to 8 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rapid visual information processing score</measure>
    <time_frame>Duration: for up to 8 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Paired Associates Learning score</measure>
    <time_frame>Duration: for up to 8 hours post-dose</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>AUC(0-t) of ACT-541468</measure>
    <time_frame>Duration: for up to 24 hours post-dose</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>AUC(0-∞) of ACT-541468</measure>
    <time_frame>Duration: for up to 24 hours post-dose</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cmax of ACT-541468</measure>
    <time_frame>Duration: for up to 24 hours post-dose</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>tmax of ACT-541468</measure>
    <time_frame>Duration: for up to 24 hours post-dose</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>t½ of ACT-541468</measure>
    <time_frame>Duration: for up to 24 hours post-dose</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Treatment-emergent adverse events (AEs)</measure>
    <time_frame>All AEs from (first) admittance on Day -1 up to EOS, i.e. for up to 9 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Treatment-emergent serious AEs (SAEs)</measure>
    <time_frame>SAE reporting: from signature of informed consent up to EOS, i.e. for up to 13 weeks</time_frame>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Healthy Recreational Drug Users</condition>
  <arm_group>
    <arm_group_label>50 mg ACT-541468</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACT-541468 will be administered as tablets for oral use.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg ACT-541468</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACT-541468 will be administered as tablets for oral use.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>150 mg ACT-541468</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACT-541468 will be administered as tablets for oral use.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>150 mg suvorexant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Suvorexant will be administered as tablets for oral use.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 mg zolpidem</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zolpidem will be administered as tablets for oral use.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered as tablets for oral use.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACT-541468</intervention_name>
    <description>ACT-541468 will be administered as 50 mg tablets for oral use.</description>
    <arm_group_label>100 mg ACT-541468</arm_group_label>
    <arm_group_label>150 mg ACT-541468</arm_group_label>
    <arm_group_label>50 mg ACT-541468</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Suvorexant</intervention_name>
    <description>Suvorexant will be administered as 15 mg over-encapsulated tablets for oral use.</description>
    <arm_group_label>150 mg suvorexant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zolpidem</intervention_name>
    <description>Zolpidem will be administered as 10 mg over-encapsulated tablets for oral use.</description>
    <arm_group_label>30 mg zolpidem</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching-placebo will be used.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent prior to any study-mandated procedure

          -  Male or female healthy subjects, 18-55 years of age (inclusive) at Screening

          -  Body mass index of 18.0-33.0 kg/m2 (inclusive) at Screening and a minimum weight of
             50.0 kg at Screening

          -  Current sedative users who have used sedatives (e.g., benzodiazepines, zolpidem,
             eszopiclone, gamma-hydroxybutyrate, barbiturates) for recreational (non-therapeutic)
             purposes (i.e., for psychoactive effects) at least ten times in their life and at
             least once in the 12 weeks before Screening

          -  Women of childbearing potential must consistently and correctly use a reliable method
             of contraception with a failure rate of &lt; 1% per year, be sexually inactive, or have a
             vasectomized partner

          -  Women of non-childbearing potential

          -  Male subjects are required to use a medically acceptable method of contraception
             throughout the entire study period and for at least 90 days after last study drug
             administration

        Exclusion Criteria:

          -  History of major medical or surgical disorders which, in the opinion of the
             investigator, are likely to interfere with the absorption, distribution, metabolism,
             or excretion of the study treatment(s)

          -  Positive HIV or hepatitis B/C test at Screening

          -  Female subjects who are currently pregnant or lactating or who are planning to become
             pregnant within 1 month of the last study treatment administration

          -  Modified Swiss Narcolepsy Scale total score &lt; 0 at Screening or history of narcolepsy
             or cataplexy

          -  Substance or alcohol dependence within 2 years prior to Screening or prior
             participation in a substance or alcohol dependence rehabilitation program

          -  Subjects who have a positive urine drug screen at admittance to the qualification or
             core phase

          -  Any sleep-disorder including self-reported insomnia disorder, breathing-related sleep
             disorders, restless legs syndrome (RLS), nightmare disorder, non-rapid eye movement
             (REM), sleep arousal disorders, REM sleep behavior disorder, circadian rhythm
             sleep-wake disorders, or narcolepsy

          -  Any of the following SLEEP-50 Questionnaire scores at Screening:

               -  ≥ 15 on Apnea subscale;

               -  ≥ 7 on Narcolepsy subscale;

               -  ≥ 7 on RLS or Periodic limb movement disorder subscale;

               -  ≥ 8 on Circadian Rhythm subscale;

               -  ≥ 7 on Sleepwalking subscale;

               -  ≥ 3 on Item 32 and ≥ 9 on Items 33 to 35 (i.e., on nightmare subscale);

               -  ≥ 15 on Impact subscale.

          -  Any circumstances or conditions, which, in the opinion of the investigator, may affect
             full participation in the study or compliance with the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Idorsia Pharmaceuticals Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Altasciences Clinical Kansas, Inc. (former Vince and Associates Clinical Research, Inc.)</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altasciences Company Inc.</name>
      <address>
        <city>Montreal</city>
        <zip>H3P 3P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 31, 2018</study_first_submitted>
  <study_first_submitted_qc>August 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2018</study_first_posted>
  <last_update_submitted>September 18, 2019</last_update_submitted>
  <last_update_submitted_qc>September 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zolpidem</mesh_term>
    <mesh_term>Suvorexant</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

